| Date | Title | Description |
| 07.08.2026 | Three Swiss biotechs widen their reach into pharma, paediatrics and lung disease |
SOPHiA GENETICS, a Rolle (VD)-based genomics company founded in 2011, runs SOPHiA DDM, a cloud platform that analyses genomic and multimodal data for hospitals, laboratories and biopharma partners. The company reported second-quarter reven... |
| 04.07.2026 | CRISPR Sickle Cell Therapy Now Cleared for Children Starting at Age Two | By Shannon Harwood
Published: Jul 04 2026, 11:24 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 23.06.2026 | «Р-Фарм» вложился в терапию гепатита В методом редактирования генома | «Р-Фарм» вложился в терапию гепатита В методом редактирования генома Технологию на основе CRISPR изначально разрабатывал Сеченовский университет
«Р-Фарм» инвестировал в разработку Сеченовского университета на основе «молекулярных ножниц» — ... |
| 23.02.2026 | FDA proposes new system for approving customized drugs and therapies for rare diseases | Getting your Trinity Audio player ready...
By MATTHEW PERRONE, AP Health Writer
WASHINGTON (AP) — Federal health officials on Monday laid out a proposal to spur development of customized treatments for patients with hard-to-treat diseases, ... |
| 07.07.2025 | Swiss Innovators celebrated worldwide |
Quantum startup ZuriQ is among the winners of the Hamamatsu bi-annual Photonics Innovation Awards 2025 that was held during the award ceremony at Laser World of Photonics, the world’s leading photonics trade fair held in Munich, Germany. A... |
| 28.05.2025 | These biotech stocks will benefit as generative AI speeds up drug discovery, Jefferies says | - |
| 15.04.2025 | Назад, в генетическое будущее | - |
| 11.02.2025 | Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand | Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand
By ReutersFebruary 10, 20259:13 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
A sign hangs in front of the world headq... |
| 15.01.2025 | The Race for AI: Innovation and Impending Doom | In the world of artificial intelligence, innovation races ahead like a speeding train. Researchers from AIRI, along with their international partners, have made headlines by reaching the finals of the prestigious Concordia Challenge. This c... |
| 14.01.2025 | Нейросети, робототехника и апокалипсис | Как повлияет развитие нейросетей и робототехники на рынок труда? Появится ли в ближайшие годы настоящий сильный ИИ? Если сильный ИИ появится - захочет ли он уничтожить человечество? Не используют ли власти большинства стран нейросети, ИИ и ... |
| 29.12.2024 | Дайджест технологий и открытий 2024 года, которые дают надежду на светлое будущее | Вот и подошел к концу 2024 год — как говорится, он был непростым… Про ИИ, полеты в космос и супермощные компьютеры и без меня написали многие. В этом дайджесте хочу вспомнить технологии и открытия, которые могли остаться для вас незамеченны... |
| 04.12.2024 | Tomorrow's Promise, Today's Roswell Park: Leaders Tackling the Biggest Priorities in Cancer Care and Treatment | From left to right, Candace S. Johnson, PhD, Cameron Nolan, Roswell Park nurse , and Michael Wong, MD, PhD, FRPC,
Roswell Park President and CEO Candace S. Johnson, PhD, today introduced the cancer center's first Physician in Chief — and th... |
| 26.09.2024 | Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say | Future of HealthRegulatory Oversight
Commercial Strategy
Regulatory
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say
By Kashish Tandon and Christy SanthoshSeptember 26, 20243:40 PM UTCUpdated ago... |
| 25.06.2024 | Exsilio Therapeutics Launches with $82 Million Series A Financing to Develop Redosable Genomic Medicines for A Broad Range of Diseases | Series A co-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, J.P. Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, Invus, Arc Ventures, and Deep Insight
Compa... |
| 14.05.2024 | CRISPR на практике. Восстанавливая зрение | Буквально на днях публиковал новость о том, что в мир вышла нейросеть, которая предлагает немалый потенциал для развития биотехнологий. И что возможности современной медицины постепенно расширяются. Что ж, мир технологий и правда не стоит н... |
| 10.05.2024 | Capsida Biotherapeutics to Present Preclinical Data for Parkinson's Disease Associated with GBA Mutations Showing High Levels of GCase Enzyme Supplementation Following IV Administration | Next-generation gene therapy demonstrates best-in-class potential with majority of neurons transduced in substantia nigra and high levels of GCase supplementation after single IV infusion
Broad GCase elevation achieved in NHPs, while signif... |
| 23.04.2024 | New report presents good figures from the Swiss biotech sector as high flyers flourish |
The overall picture of the Swiss biotech industry in the Swiss Biotech Report published today is quite positive. In addition to record revenues of CHF 7.3 billion, the industry raised more than CHF 2 billion – a remarkable 50% increase ove... |
| 01.04.2024 | Впервые в мире почку свиньи изменили генетически и пересадили человеку. Теперь их можно массово пересаживать... | Хирурги из США провели человеку трансплантацию почки, полученной из генетически модифицированной свиньи. СМИ сообщают, что данная операция является прорывом в области ксенотрансплантации, когда органы, клетки или ткани пересаживаются из одн... |
| 13.03.2024 | CRISPR Therapeutics Proposes New Appointment to the Board of Directors | - |
| 12.03.2024 | MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance | ROCKVILLE, Md., March 12, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization o... |
| 08.03.2024 | CRISPR Technology Takes Center Stage at SXSW 2024 for the First Time | - |
| 05.03.2024 | Business wind down and take off for listed Swiss startups |
Since its inception in 2012, ObsEva SA (SIX: OBSN) has focused on the development of novel therapies for women's health and pregnancy, with a program focused on improving in vitro fertilization success rates. Due to low cash reserves, the ... |
| 13.02.2024 | CRISPR Therapeutics Announces $280 Million Registered Direct Offering | - |
| 30.12.2023 | CRISPR в генотерапии. История и право | Рис.1| Здесь изображена эндонуклеаза Cas9 за работой.Введение
CRISPR – это революционная технология генной инженерии, которая позволяет точно редактировать ДНК. Применение его в генотерапии может изменить жизнь миллионов людей с генетически... |
| 05.12.2023 | Carmot’s chance of beating the odds in the biotech market just ended | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with a special thanks to everyone who joined us for STAT’s live event in New Yor... |
| 17.11.2023 | Green light for world’s first CRISPR gene-edited therapy | |
| 28.03.2023 | Up to $230 million for CRISPR Therapeutics | |
| 16.01.2023 | Какие технологии нужны ЕС? ТОП-10 технологических сфер для стартапов в Европе | Чтобы быть конкурентоспособной, Европе нужно укреплять свои позиции на рынке технологий. Мы составили топ-10 технологических сфер наиболее актуальные для Европы. Сегодня в этих отраслях наблюдается рост рабочих мест, а стартапы, которые акт... |
| 25.09.2022 | Крипта идёт в безумные стартапы, AI конструирует белки. Техдайджест | Отдел новостей 25 сентября 2022, 11:23 Крипта идёт в безумные стартапы, AI конструирует белки. Техдайджест
Каждую неделю собираем новости технологий, видео и ссылки на полезные статьи.
Оставить комментарий... |
| 11.01.2022 | CRISPR Therapeutics : Corporate Presentation | ®
Creating transformative gene-based medicines for serious diseases
Corporate Overview | Q4 2021
Forward-Looking Statements
The presentation and other related materials may contain a number of "forward-looking statements" within t... |
| 23.11.2021 | CRISPR Therapeutics : Corporate Presentation | ®
Creating transformative gene-based medicines for serious diseases
Corporate Overview | Q4 2021
Forward-Looking Statements
The presentation and other related materials may contain a number of "forward-looking statements" within t... |
| 08.11.2021 | CRISPR Therapeutics Corporate Presentation | ®
Creating transformative gene-based medicines for serious diseases
Corporate Overview | Q4 2021
Forward-Looking Statements
The presentation and other related materials may contain a number of "forward-looking statements" within t... |
| 10.08.2021 | Bringing immuno-oncology cell therapies to the masses – are we (nearly) there yet? | |
| 17.06.2021 | Capsida Partners With CRISPR Therapeutics To Treat ALS and Friedreich's Ataxia | Thousand Oaks-based startup Capsida Biotherapeutics launched in April with the goal of treating devastating diseases using gene therapy. The company just announced a big break that could accelerate its plans.
This week the company inked a d... |
| 17.06.2021 | Two Biotech Companies Team Up to Take On Rare Diseases with No Cure | Thousand Oaks-based startup Capsida Biotherapeutics launched in April with the goal of treating devastating diseases using gene therapy. The company just announced a big break that could accelerate its plans.
This week the company inked a d... |
| 07.03.2021 | "The Code Breaker": Jennifer Doudna and how CRISPR may revolutionize mankind | When Jennifer Doudna won the Nobel Prize for Chemistry last year, there was no black-tie ceremony in Sweden. Because of the pandemic, she picked up the medal in her backyard.
Correspondent David Pogue asked Doudna, "Let's cut to the re... |
| 29.12.2020 | Grants for companies fighting HIV, neurodegenerative diseases and drug resistance | |
| 29.12.2020 | Grants for companies fighting HIV, neurodegenerative diseases and drug resistance | CRISPR Therapeutics received a grant from the Bill & Melinda Gates Foundation to research in vivo gene editing therapies for the treatment of HIV. The grant builds upon CRISPR Therapeutics’ proprietary CRISPR/Cas9 gene editing technolog... |
| 16.12.2020 | Out of CRISPR pioneer David Liu's lab comes a small molecule play targeting exosites — and it's raised a modest $25M to push toward clinic | David Liu may be best known as a CRISPR trailblazer behind Editas Medicine, Beam Therapeutics and Prime Medicine. But more than six years ago, he worked with a student from his Harvard lab and then-colleague Alan Saghatelian ... |
| 07.10.2020 | ‘A terrific choice’: George Church salutes fellow CRISPR pioneers’ historic Nobel win | George Church, who is in the thick of both the science and the business of editing genomes with the now Nobel-Prize-winning technology called CRISPR, warmly greeted Wednesday’s award in chemistry to fellow pioneers Emmanuelle Charpentier an... |
| 30.09.2019 | CRISPR pioneer Feng Zhang's upstart biotech seeks $100M-plus IPO for preclinical base editing work | The CRISPR pioneers’ new, gentler-touch company is aiming for a $100 million initial public offering.
Beam Therapeutics, headed by former Editas founders and gene-editing trailblazers David Liu, Feng Zhang, and J Keith... |
| 31.05.2018 | CRISPR clinical trial hits regulatory speedbump | The companies said they expected to obtain additional information on the FDA’s questions in the near future and work toward a resolution, but they did not provide further details. The IND was submitted in April to support the Phase I/II stu... |
| 14.05.2018 | Feng Zhang and David Liu's base-editing CRISPR startup officially launches with $87M | Feng Zhang's latest CRISPR company, Beam Therapeutics, officially came out of stealth Monday with $87 million in series A funding and a mission to develop "precision genetic medicines" that use CRISPR technology to edit just one n... |
| 10.05.2018 | Should You Be Using CRISPR for Your Ag Business? | *Updated reference to Pairwise with correction regarding agreement with Monsanto*
Editor’s Note: Vonnie Estes was the 2017 recipient of Rosalind Franklin award for leadership in Biotechnology. She is an agtech innovation consultant with a p... |
| 12.04.2018 | A giant gorilla and a winged wolf: Does ‘Rampage’ get the science of CRISPR right? | We here at STAT cover CRISPR a lot. But it’s not every day we get to cover Dwayne “The Rock” Johnson.
The Rock and the genome-editing technology meet in a new movie, “Rampage,” coming out Friday. Through a freak accident, a gorilla, a wolf,... |
| 02.10.2017 | Sam Kulkarni takes the helm at CRISPR Therapeutics as founding CEO steps down | After steering CRISPR Therapeutics to an IPO last year as the last of the big three gene editing companies to make the leap into the public markets, founding CEO Rodger Novak is stepping down and handing the reins over to the... |
| 22.08.2017 | Building up its I/O ops, CRISPR Therapeutics allies with Marcela Maus at Mass General | Marcela V. Maus
CRISPR Therapeutics $CRSP is allying with some top immuno-oncology researchers at Mass General to collaborate on some new gene editing working aimed at creating a new and better generation of T cell t... |
| 19.06.2017 | China sides with Emmanulle Charpentier and Jennifer Doudna in CRISPR patent war | Continuing the patent dispute internationally, China has now given the Charpentier/Doudna side a patent to edit genes in the country.
CRISPR pioneers Emmanuelle Charpentier and Jennifer Doudna lost a patent case to the Broad Insititute earl... |
| 17.04.2017 | CRISPR Therapeutics, Casebia ink AAV deal with StrideBio; Puma gets an AdComm date; Merrimack names new R&D chief | → CRISPR Therapeutics $CRSP and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer AG, have inked a collaboration agreement with StrideBio to develop AAV vectors for in vivo gene del... |
| 03.01.2017 | Versant’s new $400M fund will be early-stage, global and appealing to Big Pharma | Fund VI adds to the very healthy pool of private investment dollars currently available to healthcare companies. In a phone interview, Versant Managing Director Brad Bolzon said the firm would continue to seek out high potential therapeutic... |
| 07.12.2016 | Kendall Square’s boarding school for biotechs | Mass Innovation Labs was late to the game, opening in May 2015. But it is clearly doing something different.
According to CEO Amrit Chaudhuri, graduates of Mass Innovation Lab’s program have collectively licensed and raised over $4 billion.... |
| 19.10.2016 | Crispr Therapeutics Announces Pricing of Initial Public Offering | Crispr Therapeutics AG (Nasdaq:CRSP), a Cambridge, MA-based biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into new medicines, today announced the pricing of its initial public offering of 4,000,000 com... |
| 19.10.2016 | Crispr Therapeutics Raises $56M for IPO | BASEL, Switzerland and CAMBRIDGE, Mass., Oct. 18, 2016 (GLOBE NEWSWIRE) — CRISPR Therapeutics AG (Nasdaq:CRSP), a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines, today anno... |
| 18.10.2016 | CRISPR Therapeutics Announces Pricing of Initial Public Offering | |
| 21.09.2016 | CRISPR Therapeutics files for $90M IPO | |
| 19.09.2016 | How Bayer Stands to Reinvent GMO with CRISPR and Monsanto Acquisition | Editor’s Note: Emma Cowan has been working in agriculture all her life after growing up on her family’s beef and soybean operation in Brazil. Her corporate career, which spans more than 25 years, includes senior positions at Rabobank, Synge... |
| 09.09.2016 | Gene editing star CRISPR Therapeutics files for $90M IPO | Emmanuelle Charpentier. Credit: Bianca Fioretti, Hallbauer & Fioretti
In one of the most highly anticipated biotech IPOs of the year, CRISPR Therapeutics has filed its S-1 outlining its plans to raise $90 million fro... |
| 09.09.2016 | Gene editing startup CRISPR Therapeutics registers for $90M IPO | The lead applications of its technology target beta thalassemia, sickle cell disease. These diseases represent a high unmet need, offer compelling market potential, and have well understood genetics, the registration statement noted. Other ... |
| 27.06.2016 | CRISPR Therapeutics Raises Additional $38M | |
| 26.06.2016 | New Leaf Venture Partners Joins $38M Series B for Crispr Therapeutics | BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines, announced an additional $38 million closi... |
| 25.06.2016 | Crispr Therapeutics Raises $38M Series B | BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines, announced an additional $38 million closi... |
| 24.06.2016 | CRISPR Therapeutics adds $38M to Series B pot, but lags behind Parker | CRISPR Therapeutics has raised an additional $38 million as part of its Series B raise, bringing its total to an impressive $140 million--but the company will not be the first to bring the gene editing tech into the clinic, with this likely... |
| 24.06.2016 | Gene-Editing Company Crispr Therapeutics Raises $38M in Series B Financing | Crispr Therapeutics, a Basel, Switzerland-based gene-editing company, raised an additional $38m in the second close of its Series B financing.
This further investment brought the total Series B financing round to nearly $140m.
This second c... |
| 12.05.2016 | After rivals’ IPOs, will CRISPR Therapeutics go public or stay buttoned-down? | It has a license to one of the biggest scientific advances in history, and its rivals have made big money on Wall Street with splashy public offerings. But CRISPR Therapeutics, the quietest member of an exclusive club with the rights to tur... |
| 19.01.2016 | Accidental snake oil: How healthcare media can hurt people | This is hugely important as biotechnology, in particular, hurtles to the forefront of the media – with new discoveries in the fields of precision medicine, immunotherapy and gene editing entrancing the broader public. It’s easy for healthca... |
| 21.12.2015 | Bayer is investing USD 335 million in an alliance with CRISPR Therapeutics | |
| 26.10.2015 | Vertex closes $105M CRISPR gene editing deal | The companies explore how to use CRISPR/Cas9 technology to correct the genetic aberrations found in cystic fibrosis and the other diseases. This new technology is attracting wide interest among the venture investment community, but it’s sti... |
| 11.08.2015 | CRISPR: Editas’ $120M proves it isn’t a bunch of hype. Here are 6 more biotechs shaping CRISPR landscape | But that’s already turned quickly on its head.
Confidence is growing in the technology, as evidenced by the title of a fantastic Wired article: “Easy DNA Editing Will Remake the World. Buckle Up.” And the broader scientific community is now... |
| 23.06.2015 | Five conspicuous omissions from MIT Tech Review’s 50 smartest companies | …we did not have trouble finding big ideas. To make the list, a company must have truly innovative technology and a business model that is both practical and ambitious, with the result that it has set the agenda in its field over the past 1... |
| 13.05.2015 | The Genome Engineering Revolution | Ryan Clarke Contributor
More posts by this contributor
A Third Act For Biofuels
James Hyun Contributor
More posts by this contributor
A Third Act For Biofuels
Editor’s note: Ryan Clarke is a biochemistry PhD candidate with an interest in ge... |
| 30.04.2015 | CRISPR Therapeutics Raises Additional $64 Million | |
| 29.04.2015 | Crispr Therapeutics Raises $64m in Series A and Series B Venture Capital Rounds | Crispr* Therapeutics, a Basel, Switzerland-based biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, raised $64m in Series A and Series B rounds, which now total $89m.
This inc... |
| 28.04.2014 | CRISPR Therapeutics raises $25 million in Series A financing | |
| 24.04.2014 | CRISPR Therapeutics Raises $25M in Series A |
BASEL, SWITZERLAND, Biopharmaceutical company focused on the breakthrough gene-editing technology CRISPR-Cas9, has raised $25 million in a series A investment from Versant Ventures.
>> Click here for more funding data on CRISPR The... |
| 24.04.2014 | Crispr Therapeutics Raises $25M in Series A Funding | Crispr Therapeutics, a Basel, Switzerland-based biopharmaceutical company that focuses on the gene-editing technology CRISPR-Cas9, raised $25m in Series A funding.
Versant Ventures made the investment.
The company intends to use the funds t... |
| - | Vertex closes $105M CRISPR gene editing deal | Vertex Pharmaceuticals is getting in on the gene editing game, teaming up with CRISPR Therapeutics in a $105 million partnership.
Vertex, the progenitor of leading cystic fibrosis therapeutics like Kalydeco, is investing $75 million in cash... |
| - | Accidental snake oil: How healthcare media can hurt people | Be careful with your words.
A new podcast from Health News Review points out the dangers of spitting out carefully crafted marketing material as news – particularly in the healthcare industry. Otherwise, it’s easy to excite the hopes of des... |
| - | Gene editing startup CRISPR Therapeutics registers for $90M IPO | Gene editing business CRISPR Therapeutics has registered for an initial public offering seeking to raise up to $90 million. CRISPR’s action is the latest in a series of IPOs in this biotech subsector following Editas Medicine and Intellia T... |
| - | Five conspicuous omissions from MIT Tech Review’s 50 smartest companies | We know who made the cut in the latest MIT Technology Review list of the 50 Smartest Companies of 2015.
But there were a few conspicuous omissions – take Theranos, for instance, or Alexion Pharmaceuticals – from the otherwise meaty list of ... |
| - | Kendall Square’s boarding school for biotechs | A communal area at the Mass Innovation Labs facility
It’s hard to get excited about a biotech shared-space in 2016.
Four years ago, it was an exciting and rapidly diversifying field. Now incubators are par for the course, with most Big Phar... |
| - | CRISPR: Editas’ $120M proves it isn’t a bunch of hype. Here are 6 more biotechs shaping CRISPR landscape | CRISPR/Cas9 gene editing has zoomed to the forefront of the biotech investment scape in the past year — punctuated this week by Editas Medicine‘s impressive $120 million fundraise. Looks like it’s no longer hype — there’s solid funding to p... |
| - | CRISPR clinical trial hits regulatory speedbump | Regulators hit the brakes on a gene-editing therapy train before it even left the station.
CRISPR Therapeutics and Vertex Pharmaceuticals said Wednesday that the Food and Drug Administration placed a clinical hold on their application to st... |
| - | Versant’s new $400M fund will be early-stage, global and appealing to Big Pharma | Brad Bolzon, managing director of Versant Ventures
It’s a new year and a new pot of cash for Versant Ventures.
The firm announced Tuesday that it had closed Versant Venture Capital VI, reaching its hard cap of $400 million — $50 million mor... |
